NJ-LTIMINDTREE
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced a collaboration with IBM to establish a global, joint Generative AI Center of Excellence (CoE) in India, a co-innovation center combining the power of the IBM watsonx AI and data platform and the engineering skills of LTIMindtree.
Open innovation drives the growth of enterprise AI technology, helping organizations apply AI-infused solutions to solve business challenges. It is this same open innovation which plays a key role in the LTIMindtree and IBM collaboration.
The LTIMindtree and IBM CoE plans to offer a comprehensive suite of services, combining LTIMindtree's expertise in data and machine learning model customization and full-stack engineering with IBM watsonx technology including watsonx.ai, watsonx.data, and watsonx.governance, and AI assistants. The center, located in India, will focus on building point solutions to accelerate clients’ generative AI adoption journeys.
Nachiket Deshpande, COO and Whole-time Director, LTIMindtree, commenting on the collaboration, said, “Open innovation is the cornerstone of progress in the digital era. By joining forces with IBM, LTIMindtree aims to be at the forefront of advancing AI technologies and empowering businesses to achieve unparalleled success with governance.”
Kate Woolley, General Manager, IBM Ecosystem said, “IBM Service Partners such as LTIMindtree play an integral role helping enterprises maximize the benefits of generative AI technology through all phases of their AI adoption journey. Our collaboration, distinguished by the Center of Excellence, is an opportunity for our companies to work closely together to help funnel the latest AI research and innovations into technologies solving real-world business challenges.”
This collaboration is expected to offer various benefits to clients, including providing them access to the following:
- IBM watsonx.governance: LTIMindtree will offer a watsonx.governance integration with the Canvas.ai platform, resulting in a collaborative enterprise-ready toolkit that enables organizations to strategically incorporate AI governance frameworks throughout the entire AI lifecycle. Together, these platforms will provide users with the structure and processes necessary to help them navigate the complexities of the regulatory landscape while also adhering to ethical standards, compliance requirements, and responsible AI practices.
- IBM watsonx.data: The CoE will also offer an enterprise data modernization and warehouse augmentation service powered by watsonx.data. This service will provide the framework and tools for data warehouse consumers to augment the performance of their existing data warehouse capabilities using the power of IBM watsonx.data and LTIMindtree's expertise in crafting tailored solutions.
- IBM watsonx.ai: The CoE is also expected to provide a suite of services dedicated to modernizing full-stack applications across a set of domain specific use cases, including mainframe application modernization use cases. LTIMindtree's proficiency in full-stack engineering, combined with the powerful IBM watsonx.ai studio, will help enterprises train, validate, tune and deploy AI models while simplifying their modernization efforts.
The Center of Excellence aims to play a pivotal role in expanding the scope of generative AI applications for digital initiatives of clients, utilizing the IBM watsonx platform and AI assistants, machine learning, speech recognition, natural language processing, and conversational AI to augment end user experience.
Clients interested in learning more about this collaboration can meet LTIMindtree at IBM THINK in Boston. For more information on LTIMindtree’s offerings with IBM, please visit https://www.ltimindtree.com/enterprise-solutions/ibm/
About LTIMindtree
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 81,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/.
About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506254574/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release
79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release
Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom